Please assess the completion status of the following clinical trial:

Trial Title: Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer~  * Early-stage, operable disease~* Scheduled to receive adjuvant or neoadjuvant systemic chemotherapy for breast cancer~* Hormone receptor status:~  * Meets 1 of the following criteria:~    * Estrogen receptor (ER)- OR progesterone receptor (PR)-positive~   * ER- AND PR-negative~* No history of premature ovarian failure~PATIENT CHARACTERISTICS:~Age~* Under 45~Sex~* Female~Menopausal status~* Premenopausal~  * Follicle-stimulating hormone levels \< 40 IU/L at baseline AND at least 2 menstrual periods within the past 6 months~* No first-degree relative menopausal at \< 40 years of age~Performance status~* Eastern Cooperative Oncology Group \[ECOG\] 0-1~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* Not pregnant or nursing~* Fertile patients must use effective non-hormonal methods of contraception~* No prior osteoporosis or other non-malignant systemic disease that would preclude prolonged follow-up~* No known allergies to gonadotrophin-releasing hormone agonists~* No other cancer except nonmelanoma skin cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~* No prior chemotherapy~Endocrine therapy~* At least 2 weeks since prior oral contraceptives~* No prior fertility treatment~  * Clomiphene or pergonal for polycystic ovarian disease allowed~* No other concurrent oral or transdermal hormonal therapy, including any of the following:~  * Estrogen~ * Progesterone~ * Androgens~ * Aromatase inhibitors~ * Hormone replacement therapy~ * Oral contraceptives~Radiotherapy~* No prior ovarian radiotherapy~Surgery~* No prior bilateral oophorectomy~* No plans for oophorectomy or hysterectomy within the next 2 years~Other~* At least 1 week since prior warfarin~Exclusion Criteria:~* History of premature ovarian failure~* Over 45 years of age~* First-degree relative menopausal at \< 40 years of age~* Pregnant or nursing~* Prior osteoporosis or other non-malignant systemic disease that would preclude prolonged follow-up~* Known allergies to gonadotrophin-releasing hormone agonists~* Other cancer besides nonmelanoma skin cancer~* Prior chemotherapy~* Prior ovarian radiotherapy~* Prior bilateral oophorectomy

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 44 Years
- Healthy Volunteers: f

Study Arms:
- triptorelin (Type: EXPERIMENTAL): GnRH analogue (triptorelin) during chemotherapy
- no triptorelin (Type: NO_INTERVENTION): No GnRH analogue (triptorelin) during chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues